← Eichor
Study identifier: NCT04991831 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

Condition: Tremor Associated With Tremor Dominant Parkinson's Disease  ·  Sponsor: InSightec

PhaseN/A
Planned participants50
Who can joinAll sexes, 30 Years to 99 Years
Healthy volunteersNo

About this study

The objectives of this study are to collect the long-term safety and effectiveness data of performing thalamotomy for tremor dominant Parkinson's Disease (TDPD) using the Exablate Neuro system.

This description comes directly from the study's public registry record.

Talk to the study team

Matt Hibert  ·  214-630-2000  ·  clinicalresearchquestions@insightec.com

Always discuss trial participation with your own doctor first.

Locations (8)

Miami Neuroscience Institute Baptist HealthMiami, Florida, United StatesRecruiting
Rush UniversityChicago, Illinois, United StatesRecruiting
Brigham and Women's HospitalBoston, Massachusetts, United StatesRecruiting
Weill Cornell MedicineNew York, New York, United StatesRecruiting
Novant Health Brain & Spine SurgeryHuntsville, North Carolina, United StatesRecruiting
Cleveland Clinic FoundationCleveland, Ohio, United StatesRecruiting
Miami Valley HospitalFairborn, Ohio, United StatesRecruiting
University of DundeeDundee, Scotland, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04991831